|
|
|
International Clinical Trials
|
“Today, 47 million people live with dementia worldwide, more than the population of Spain. This number is projected to increase to more than 131 million by 2050, as populations age. Dementia also has a huge economic impact. The total estimated worldwide cost of dementia is US$818 billion, and it will become a trillion dollar disease by 2018” (1).
Because of the social impact of this chronic neurodegenerative disease, it has become a major target for new therapies and, together with Parkinson’s, accounts for approximately a third of all neurological trials initiated over the past five years (2). Despite this, the success of new medicines in the area is poor. At present, the only products on the market are Cholinesterase inhibitors and N-methyl-D-asparate (NMDA) antagonists, providing symptomatic therapy. Consequently, the drive for diseasemodifying treatments is huge, and, despite major setbacks for drugs in trials to date, in 2016, 51 Alzheimer’s trials were initiated compared to five in 2002 (3,4). Dominantly Inherited Alzheimer Network Trial (DIAN-TU) represents a new frontier for assessing the impact of disease-modifying drugs as it targets patients with a genetic predisposition and starts treatment prophylactically.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
PHARM Connect 2019
Life science and business are going to meet at PHARM Connect on the
12-13 of March 2019 in Budapest, Hungary to continue the tradition of
providing high calibre, customised professional partnering opportunities
for pharma and biotech professionals from Central & Eastern
European and beyond and deliver the crucial information they need to
excel in their work. The influential annual gathering brings together
over 400 global and regional decision-makers, top scientists, industry
executives and business development leaders for the ninth time to
identify new business opportunities, technologies, state-of-the-art
formulation development strategies and to foster exchange of ideas on
the role of the sector.
More info >> |
|
 |
White Papers |
 |
|
Technology Solutions - Driving efficiencies, quality and operational excellence
Worldwide Clinical Trials Ltd
Clinical trials involve the entry, analysis and reporting of millions of pieces of data; year-on-year, the amount of data required to manage efficacy and safety increases exponentially. Recently, solutions available to support this activity have grown in numbers and complexity. The rise of Tablets and Smart Phones combined with the growth of Cloud or SAS solutions has resulted in the technology landscape required to support complex, global studies becoming more confusing.
More info >> |
|
 |
Industry Events |
 |
World Advanced Therapies & Regenerative Medicine Congress 2019
15-17 May 2019, Business Design Centre, London
The World Advanced Therapies & Regenerative
Medicine Congress is an exhibition and conference that has grown to become one
of the best and most established cell and gene events in the world today.
The 2019 edition will be in its 14th year and it continues to grow and attract
a large audience of biotech, pharma, start-ups, investors, research and
technology companies from around the world. The conference and exhibition will
host over 1000 attendees, 250 speakers and 80 exhibition booths. Over 500
different global companies are represented every year at this event.
More info >> |
|
|
